https://www.engadget.com/instagram-tests-desktop-posting-162209909.html
Needham Maintains Buy on Cellebrite DI, Lowers Price Target to $9.5
Needham analyst Mike Cikos maintains Cellebrite DI (NASDAQ:CLBT) with a Buy and lowers the price target from $12 to $9.5.